Privately held anticoagulant drug developer Portola Pharmaceuticals Inc. one day may face competition from Pfizer Inc. and Bristol-Myers Squibb Co. if their Factor Xa inhibitor compounds are approved. But for now, Portola has partnered with the two pharmas on an antidote compound designed to stanch serious bleeding in patients who take anticoagulants in that class.
Portola said Nov. 1 that Pfizer and Bristol will fund a proof-of-concept study of PRT4445, Portola’s antidote that reverses the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?